Valenzabio, Inc., A Biopharmaceutical Company Developing Monoclonal Antibody (Mab) Therapeutics For Autoimmune And Inflammatory Indications, And Novelty Nobility Inc, A Biotechnology Company Specializing In The Design, Discovery, Optimization, And Early Stage Development Of Next Generation Antibodies, Today Announced An Exclusive Worldwide License Agreement For The Development And Commercialization Of Vb517, A Potentially Best-In-Class Anti-C-Kit Mab For Mast Cell-Driven Autoimmune Diseases. C-Kit Is A Receptor Tyrosine Kinase Critical To The Survival And Activation Of Mast Cells. Blocking C-Kit Has Been Shown To Reduce Mast Cell Degranulation And Induce Mast Cell Depletion In Clinical Studies. Vb517 Is A Fully Human Mab With Low-Picomolar Affinity For C-Kit And Has Demonstrated Potent Suppression Of Human Mast Cell Activation In Preclinical Models. Valenzabio Plans To Initiate Clinical Studies Of Vb517 In 2023.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!